The investigational drug ALN‐VSP administered intravenously, was safe and well‐tolerated, demonstrating efficacy through observable anti‐VEGF and anti‐KSP effects in patients.[7] Numerous RNAi targets have been identified, influencing HCC therapy and augmenting other therapeutic modalities, offering new possibilities for HCC treatment. Here, VEGFA is linked to hepatocellular carcinoma.